Biotech · Public company · Foster City, CA, US

Geron Corp

Ticker GERN · SEC CIK 0000886744

Track this companyFree. Adds Geron Corp to your Dealase workspace and tells you when its record changes.

Clinical trials96 recruiting or active

Pipeline programs10From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline10

Best Available Therapy (BAT)Phase 3 · MyelofibrosisClinicalTrials.gov · fetched Nov 12, 2026
ImetelstatPhase 3 · MyelofibrosisClinicalTrials.gov · fetched Nov 12, 2026
Imetelstat SodiumPhase 3 · Myelodysplastic SyndromesClinicalTrials.gov · fetched Nov 12, 2026
ImetelstatPhase 2 · Primary MyelofibrosisClinicalTrials.gov · fetched Nov 12, 2026
Imetelstat (7.5 mg/kg)Phase 2 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
Imetelstat (9.4 mg/kg)Phase 2 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
Imetelstat 4.7 mg/kgPhase 2 · MyelofibrosisClinicalTrials.gov · fetched Nov 12, 2026
Imetelstat 9.4 mg/kgPhase 2 · MyelofibrosisClinicalTrials.gov · fetched Nov 12, 2026
Imetelstat sodiumPhase 1 · MyelofibrosisClinicalTrials.gov · fetched Nov 12, 2026
RuxolitinibPhase 1 · MyelofibrosisClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials9

Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCTPHASE1 · NOT_YET_RECRUITING · started Feb 1, 2027ClinicalTrials.gov NCT07909733 · fetched Nov 12, 2026
Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative NeoplasmsPHASE2 · NOT_YET_RECRUITING · started Oct 8, 2026ClinicalTrials.gov NCT07549451 · fetched Nov 12, 2026
Imetelstat Combinations in Relapsed AMLPHASE1 · RECRUITING · started Jan 2, 2026ClinicalTrials.gov NCT07320235 · fetched Nov 12, 2026
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With MyelofibrosisPHASE1 · ACTIVE_NOT_RECRUITING · started May 4, 2022ClinicalTrials.gov NCT05371964 · fetched Nov 12, 2026
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor TreatmentPHASE3 · ACTIVE_NOT_RECRUITING · started Apr 12, 2021ClinicalTrials.gov NCT04576156 · fetched Nov 12, 2026
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)PHASE2_PHASE3 · ACTIVE_NOT_RECRUITING · started Jan 12, 2016ClinicalTrials.gov NCT02598661 · fetched Nov 12, 2026
Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) InhibitorPHASE2 · COMPLETED · started Aug 28, 2015ClinicalTrials.gov NCT02426086 · fetched Nov 12, 2026
Imetelstat Sodium in Treating Participants With Primary or Secondary MyelofibrosisPHASE2 · COMPLETED · started Oct 29, 2012ClinicalTrials.gov NCT01731951 · fetched Nov 12, 2026
Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple MyelomaPHASE2 · COMPLETED · started Nov 1, 2010ClinicalTrials.gov NCT01242930 · fetched Nov 12, 2026

SEC filings12

10-Q · 10-QSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Oct 28, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed Aug 5, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed May 27, 2026 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed May 6, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Mar 26, 2026 · fetched Nov 12, 2026
10-K · 10-KSEC EDGAR · filed Mar 2, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Feb 25, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jan 12, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jan 6, 2026 · fetched Nov 12, 2026